Ilomedine (Iloprost Trometamol)

Iloprost Trometamol is a synthetic prostacyclin analogue that activates the IP (prostacyclin) receptor on vascular smooth‑muscle cells. This activation raises intracellular cyclic‑AMP levels, causing potent vasodilation and reducing platelet aggregation, which together lower pulmonary arterial pressure and enhance microcirculatory flow.

The dosing regimen for Ilomedine is individualized. A qualified prescriber determines the appropriate infusion rate, concentration, and duration based on the patient’s clinical condition, response, and tolerance. Specific dosing instructions are provided in the product’s prescribing information and should not be altered without medical guidance.

Safety data for Ilomedine in pregnancy and lactation are limited. The product’s pregnancy category is unknown, and it is generally recommended to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a healthcare professional is essential before use.

To order Ilomedine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling if needed), and required import documentation.

Ilomedine (iloprost trometamol) is a short‑acting prostacyclin analogue administered intravenously, whereas alternatives such as epoprostenol are also short‑acting but may require continuous infusion. Iloprost has a slightly longer half‑life, allowing intermittent dosing in some protocols, and is often chosen for its established efficacy in digital ulcer healing and peripheral arterial disease.

Ilomedine should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Before use, inspect the product for particulate matter or discoloration and follow aseptic techniques for preparation and administration.

Ilomedine is supplied as a sterile solution for injection and is administered intravenously. The infusion is typically delivered through a controlled infusion pump or syringe driver, with the rate adjusted according to the prescriber’s instructions and patient tolerance. Continuous monitoring of vital signs is recommended during the infusion.

The most serious adverse reactions include severe hypotension, pulmonary edema, and bleeding complications due to platelet inhibition. Patients should be closely monitored for sudden drops in blood pressure, signs of fluid accumulation in the lungs, and any unexpected bleeding, especially if they are receiving anticoagulants or other vasodilators.

Ilomedine is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation. Caution is also advised for individuals with uncontrolled hypotension, active bleeding disorders, or severe renal impairment. Pregnant or breastfeeding women should only use the drug if the potential benefit outweighs the risk.